S&P 500 falls after giving up gains as Oracle slump weighs on tech
Dentsply Sirona Inc (XRAY) stock has reached a 52-week low, touching a price of 12.15 USD. According to InvestingPro data, the company maintains a significant 5.24% dividend yield and has maintained dividend payments for 32 consecutive years. This milestone reflects a significant downturn for the company, as it has experienced a 54.27% decrease over the past year. While the dental equipment manufacturer has faced various challenges, contributing to this sharp decline in stock value, InvestingPro analysis indicates the company is currently undervalued, with 7 analysts revising their earnings upward for the upcoming period. Investors are closely monitoring the situation, as the company navigates through market pressures and seeks to stabilize its financial standing, with analysts predicting a return to profitability this year. For deeper insights and additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Dentsply Sirona reported its second-quarter earnings for 2025, exceeding expectations with earnings per share (EPS) of $0.52, slightly above the forecast of $0.50. The company’s revenue was $936 million, surpassing the expected $933.63 million, though it represented a 5% decline from the previous year. In addition, Dentsply Sirona awarded a $2 million retention grant to its Chief Supply Chain Officer, Tony Johnson, to acknowledge his performance and encourage his continued employment. Analyst firm Needham maintained its Hold rating on Dentsply Sirona following their DS World event. Meanwhile, Mizuho lowered its price target for the company to $16.00, citing concerns about margins and taxes. Jefferies also reduced its price target to $15.00 due to tariff concerns, despite the company’s earnings and sales slightly exceeding prior estimates. These developments highlight the company’s recent performance and strategic decisions in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.